Efficacy
toxicity, Deaths, prostate
RECURRENCE, DISEASE, PROSTATE, HEAD AND NECK CANCER, LYMPH NODE METASTASIS, METASTASES
At a median follow-up time of 61 months (range 48 to 110 months), 10 out of 33 patients had a PSA recurrence (30.3%), (Two patients had distant metastases only; three patients had lymph node metastasis only; one patient had lymph node metastasis with concomitant intraprostatic in-field recurrence; two patients had in-field prostate recurrence only; and two patients had biochemical failure without evidence of metabolically active disease. Among the three patients with a local intraprostatic recurrence, one of them recurred in the area of the SIB-DIN which received 50 Gy while the other two patients recurred outside the SIB-DIN in the area that received 36.25 Gy and had no MRI recognizable nodule prior to treatment.(Among the 10 patients with recurrence, 40% had an initial T3a/b disease and/or Gleason score≥8. Three patients died during study follow-up: one from metastatic PCa, one from COVID-19, and one from head and neck cancer. Deaths occurred after patients completed the first 3 months toxicity period evaluation (primary endpoint).